The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.
Jun 2, 2020 at 9:30 AM EDT
Aug 6, 2020 at 4:30 PM EDT Investor Relations; Events; Channel Partners; NGS ProLab; Contact; Twist blog; BIOPHARMA; Twist Bioscience.
Twist has proven itself to be a true next-generation DNA synthesis supplier, with the capacity to rapidly provide 1000s of genes at a price keenly awaited by the user community for many years.
Jun 11, 2020 Twist Bioscience Expands Offering of Synthetic SARS-CoV-2 RNA Controls Keep Reading . Twist Bioscience Customer Vanderbilt University Medical Center (VUMC) Announces Publication of Positive Preclinical Results on Neutralizing Antibodies as a Potential Therapy for Preventing and Treating COVID-19
July 23, 2020 14 min read Science. Twist Bioscience Expands Offering of Synthetic SARS-CoV-2 RNA Controls
Twist Bioscience. Start the day with a saliva sample, and end the day with the samples on a sequencer!
Investor Relations Global Contacts Business Wire Twist Bioscience to Report Fiscal 2020 Third Quarter Financial Results on Thursday, August 6, 2020 Provided by Business Wire. Saliva sample to sequencer in under 8 hours .
Twist Bioscience Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19 Twist Bioscience Launches Synthetic Controls for Respiratory Viruses Data Provided by Refinitiv. Twist Bioscience Adds Respiratory Virus Panel to Infectious Disease Product Line Development of an 8-hour saliva sequencing workflow. Minimum 15 minutes delayed.We are a leading, rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Takeda Partners with Twist Bioscience to Expand Biologics Discovery Capabilities
Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Investor Relations Press Releases Press Releases Year.
Simon Charnock, Technical Director, Prozomix
Twist Bioscience Appoints Erin Smith Senior Vice President, Government Affairs and Public Policy Twist Bioscience Adds Respiratory Virus Panel to Infectious Disease Product Line Keep Reading . 30, 2020-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2020 third quarter ended June 30, 2020, following the close of market on Thursday, August 6, …
The Investor Relations website contains information about Twist Bioscience's business for stockholders, potential investors, and financial analysts. Jun 08, 2020 Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to … Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats July 23, 2020 14 min read The following blog … SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul.
Twist Bioscience to Report Fiscal 2020 Third Quarter Financial Results on Thursday, August 6, 2020 May 19, 2020 at 10:00 AM EDT